Glaucoma is a general grouping of eye diseases that impact the optic nerve, resulting in progressive vision loss. According to the NIH National Eye Institute, currently, over 2.7 million Americans suffer from glaucoma, and approximately 11 million are projected to be afflicted by 2050. For many years, clinicians have struggled to find an efficacious treatment for glaucoma. To date, first-line drugs have had limited effectiveness due to progression of the disease or low patient compliance, and conventional surgical methods lacked the efficacy to produce a long-term cure. In the late 1990s, researchers began thinking about non-traditional approaches for
Professor Aimee Edinger and her lab’s researchers, while unpinning the fundamental mechanisms of tumor biology, are designing out-of-the-box therapies to fight cancer. In collaboration with medicinal chemist, Prof. Stephen Hanessian of UCI and University of Montréal, they are taking unprecedented steps in understanding and designing a treatment that targets a universal hallmark of all cancers, the high metabolic demand that sustains rapid, uncontrolled growth.
ZAP! is a training program designed for university researchers interested in translating their research into the marketplace. It is a compressed version of the National Science Foundation (NSF) Innovation Corps (I-Corps) program. The aims of ZAP! are to broaden the focus of scientists and engineers outside of the laboratory and facilitate the advancement of their research towards commercial products and entrepreneurial pursuits. As lead trainer of the two-day seminar, Farzin Samadani of the Innovation Node at Los Angeles pointed out early on that “we’re not here to pick winners.” Participants were taught the fundamentals of market research, including how to conduct, gather, and analyze industry and customer research to facilitate their technology development process and
The UC Center for Accelerated Innovation (CAI) is a collaborative group comprised of five of the UC medical campuses. The mission of the group is to improve health care and address unmet medical needs through translation of biomedical discoveries at the universities. The collective applies business and product development practices from industry to advance promising technologies toward commercialization. The focus of the Medical Device Retreat, moderated by UCI Professor and CAI Site Leader, Elliot Botvinick, was to educate biomedical researchers on the essentials of starting a business and building intellectual property. The purpose of this training was to give researchers the foundational understanding of developing products and starting a business, for which they could apply elements into their research project pipelines, as well as help strengthen their
This year’s annual Micro and Nanofluidics Symposium, hosted at UCI, was opened and closed with remarks from UCSB Prof. Sumita Pennathur. She emphasized that the goal of this closed-door symposium series is for researchers to freely share their innovative ideas and latest discoveries to inspire and help each other. Over the course of the two day symposium, researchers from UCI, UCLA, and UCSB Schools of Engineering gathered to attend presentations from invited speakers, UCI Prof. Elliot Botvinick and UCSB Prof. Luke Theogarajan, as well as other faculty, graduate students, and postdoctoral fellows.
The device is an artificial corneal implant comprised of a single, nanopatterned material. The device is durable, easy to implant, and robust against bacterial infection and other problems associated with other state-of-the-art ocular devices.